Eli Lilly unit accuses Alzheimer's institute of ‘malicious’ patent prosecution
Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, has taken the Alzheimer's Institute of America (AIA) to court over its “malicious” prosecution of a patent infringement case.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
22 July 2021 The US Patent Trial and Appeal Board has given the go-ahead for an inter partes review of a Chinese pharma company’s US patent related to a treatment for Alzheimer’s.
22 July 2021 The US Patent Trial and Appeal Board has given the go-ahead for an inter partes review of a Chinese pharma company’s US patent related to a treatment for Alzheimer’s.
22 July 2021 The US Patent Trial and Appeal Board has given the go-ahead for an inter partes review of a Chinese pharma company’s US patent related to a treatment for Alzheimer’s.